WASHINGTON, DC, Oct. 3 – Pluvita, a drug-discovery and development company, has acquired a majority stake in Diogenics, a privately held genomic firm, the companies said on Wednesday.

The acquisition, for an undisclosed amount, was designed to allow Pluvita to combine its bioinformatics, information management, and clinical databases with Diogenics’ wet-lab capabilities, model systems, and intellectual property assets, Pluvita said in a statement.  

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.